摘要
Romosozumab是一种新型抗骨质疏松药物,可作为绝经后骨质疏松症患者治疗方案选择之一。近期,美国内分泌学会就该药治疗适应证及证据进行归纳总结,并于2020年2月发表在J Clin Endocrinol Metab杂志上,旨在对美国内分泌学会2019年发布的《关于绝经后骨质疏松症药物合理治疗临床实践指南》进行更新。本文就该指南更新的主要内容进行简要解读。
Romosozumab is a new anti-osteoporotic drug,which can be used as one of the treatment options for postmenopausal osteoporosis patients.Recently,the American Endocrine Society has summarized the indications and evidence for the treatment of Romosozumab,and published it in the J Clin Endocrinol Metab in February 2020 to update“Pharmacological Management of Osteoporosis in Postmenopausal Women:An Endocrine Society*Clinical Practice Guideline”by the American Endocrine Society in 2019.This paper briefly interprets the main contents of the updated guidelines.
作者
符善姜
欧阳娜
盛志峰
FU Shan-jiang;OUYANG Na;SHENG Zhi-feng(Department of Metabolism and Endocrinology,Sanya Central Hospital(The Third people's Hospital of Hainan Province),Sanya 572000,Hainan,China;Department of Metabolism and Endocrinology,National Clinical Research Center for Metabolic Diseases,Hunan Key Laboratory for Metabolic Bone Diseases,Health Management Center,the Second Xiangya Hospital of Central South University,Changsha 410011,China;Hospital Infection Control Center,the Second Xiangya Hospital of Central South University,Changsha 410011,China)
出处
《中华骨质疏松和骨矿盐疾病杂志》
CSCD
北大核心
2020年第6期570-576,共7页
Chinese Journal Of Osteoporosis And Bone Mineral Research
基金
国家自然科学基金(81471091,81870622)
湖南省自然科学基金(2018JJ2574)
白求恩公益基金会项目(G-X-2019-1107-3)。
